Management of Acute Gastric Ulcer Bleeding by Christo van Rensburg & Monique Marais
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
16 
Management of Acute Gastric  
Ulcer Bleeding 
Christo van Rensburg and Monique Marais 
Stellenbosch University 
South Africa 
1. Introduction  
Acute gastric ulcer bleeding frequently presents as a gastrointestinal emergency. It has 
important implications for healthcare costs worldwide. Negative consequences include 
rebleeding and death usually caused by the functional worsening of concomitant medical 
conditions, precipitated by the acute bleeding incident. Advances in medical practice in 
recent decades have influenced the aetiology and management of upper gastrointestinal 
bleeding (UGIB), but their impact on the incidence and mortality is unclear. 
2. Epidemiology 
At one time peptic ulcer disease accounted for 50–70% of acute non-variceal UGIB (Barkun 
et al., 2004). Approximately 80% of these ulcers stop bleeding spontaneously. Gastric ulcer is 
more frequently the source of UGIB (55% versus 37%); compared to duodenal ulcer 
(Enestvedt et al., 2008). The current practice to use proton pump inhibitors as ulcer 
prophylaxis and eradication of Helicobacter pylori, has led to a worldwide decrease in the 
incidence of bleeding from peptic ulcer. However, this seems applicable only to patients 
younger than 70 years of age (Lanas et al., 2005; Loperfido et al., 2009; Targownik et al., 
2006). Recent population-based estimates have suggested that the incidence is about 60 per 
100,000 of the population (Lassen et al., 2006), with the incidences related to the use of 
aspirin and non-steroidal anti-inflammatory drugs on the increase (Ohmann et al., 2005). 
The mortality associated with peptic ulcer bleeding remains high at 5 to 10% (Lim et al., 
2006). The estimated direct medical costs annually incurred in the United States for the in-
hospital care of patients with peptic ulcer bleeding amounts to a total of more than $2 billion 
(Viviane et al., 2008).  
3. Pathophysiology 
3.1 Risk factors 
There are four major risk factors for bleeding peptic ulcers namely Helicobacter pylori 
infection, non-steroidal anti-inflammatory drugs (NSAIDs), stress and gastric acid (Hunt et 
al., 1995; Hallas et al., 1995). Reduction or elimination of these risk factors lessens ulcer 
recurrence and rebleeding rates (Graham et al., 1993; Tytgat 1995).  
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3.1.1 Helicobacter pylori 
Compared to non-bleeding duodenal ulcers (70–90%), Helicobacter pylori plays a lesser role in 
the aetiology of bleeding and gastric ulcers (Maury et al., 2004). However, it is important to 
exclude Helicobacter pylori as a factor in the aetiology.  
Helicobacter pylori eradication should be attempted in all peptic ulcer patients diagnosed 
with the infection to prevent ulcer recurrence and rebleeding (Hopkins et al., 1996). In 
Hopkin’s report of 19 published studies, the recurrence rates in cured versus uncured 
Helicobacter pylori infection was 6% versus 67% for duodenal ulcer, and 4% versus 59% for 
gastric ulcer. Various regimens that usually combine one or two antibiotics plus an anti-
secretory agent have eradication rates that vary between 80% and 90% (Walsh et al., 1995). 
3.1.2 Non-steroidal anti-inflammatory drugs 
NSAIDs, including aspirin, frequently cause gastrointestinal ulceration (Lanas et al., 2005; 
Scheiman 1994). NSAID-induced injury results from both local effects and systemic 
prostaglandin inhibition effected by blocking cyclooxygenase-1. The majority of these ulcers 
are asymptomatic and uncomplicated. However, elderly patients with a prior history of 
bleeding ulcer disease are at increased risk for recurrent ulcer and complications (Hansen et 
al., 1996; Smalley et al., 1995). NSAIDs are also implicated as critical in the non-healing of 
ulcers (Lanas et al., 1995). Aspirin in dosages as low as 75 mg daily transfer an increased risk 
of ulcers and bleeding (Lim et al., 2004).  
Combining corticosteroids with NSAIDs doubles the risk of ulcer complications whilst the 
risk of gastrointestinal bleeding is increased ten fold (Piper et al., 1991). Cyclooxygenase-2 
inhibitors reduce the risk of ulcer bleeding only when not combined with aspirin therapy. 
Of concern, is the increase in incidence of myocardial infarction and cerebrovascular 
accidents in patients taking selective cyclooxygenase-2 inhibitors. The combination of 
Helicobacter pylori infection and NSAID use may increase the risk of ulcer bleeding; however, 
the need for eradication of Helicobacter pylori in patients who are taking NSAIDs remains 
controversial. (al-Assi et al., 1996).  
3.1.3 Stress-related ulcers 
The incidence of stress-related ulcers in intensive care units (ICU) is approximately 0.67. 
This form of ulceration tends to occur in severely ill patients and is almost certainly 
triggered by ischaemia due to a combination of decreased mucosal protection and reduced 
mucosal blood flow (Cooper et al., 1999). It is a frequent cause of acute UGIB in patients who 
are hospitalized for life-threatening non-bleeding illnesses (Navab et al., 1995). The risk of 
stress ulcer-related bleeding is increased in patients with respiratory failure and those with a 
bleeding disorder (Cook et al., 1994). Also, the mortality is higher in patients that present 
with a UGIB after hospitalization compared to those primarily admitted with UGIB 
(Zimmerman et al. 1994).  
Primary ulcer prophylaxis with anti-secretory agents such as H2–receptor antagonists or 
proton pumps inhibitors (PPIs) decreases the risk of stress-related mucosal damage and 
UGIB in high-risk patients (Cook et al., 1996). Achlorhydria associated with prophylactic 
acid inhibition effects bacterial growth in the stomach and possible ventilator-associated 
pneumonia in ICU patients. Furthermore, stress-related ulcers tend to have high rebleeding 
rates and are not as amenable to endoscopic therapy as patients that present to the hospital 
with bleeding peptic ulcer (Jensen et al., 1988). 
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3.1.4 Gastric acid 
Gastric acid and pepsin are essential cofactors in the pathogenesis of peptic ulcer (Peterson 
et al., 1995). Factors such as Helicobacter pylori, NSAIDs, or physiologic stress impair the 
mucosal integrity leading to increased cell membrane permeability and back diffusion of 
hydrogen ions, resulting in intramural acidosis, cell death, and ulceration. Hyperacidity as is 
prevalent in patients with Zollinger-Ellison syndrome, is rarely the sole cause of peptic 
ulceration. However, control of gastric acidity is considered an essential therapeutic 
manoeuvre in patients with active UGIB. 
4. Acute management (Figure 1) 
Patients with acute gastric ulcer bleeding frequently present with haematemesis (vomiting 
of red blood that is suggestive of active bleeding or vomiting of coffee-ground material 
indicative of older non-active bleeding) and/or melaena (black tarry stools which suggests 
passage of old blood, usually from an upper gastrointestinal source). Haematochezia (the 
passage of red blood per rectum) can occasionally be due to massive UGIB as suggested by a 
hypotensive or shocked patient. Patients who presents with haematemesis and melaena 
generally have more severe bleeding than those who present with melaena only. Immediate 
evaluation and appropriate resuscitation are critical as these can reduce mortality in acute 
UGIB (Baradarian et al., 2004). 
4.1 Resuscitation and stabilization 
As first priority, the haemodynamic stability (pulse and blood pressure, including 
orthostatic changes) and the need for fluid replacement must initially be assessed at 
presentation of a patient with UGIB. A full blood count, urea, electrolytes, creatinine, 
international normalized ratio (INR), blood type and cross-match should be obtained. If 
indicated, volume resuscitation should be initiated with crystalloids and blood products in 
all patients with haemodynamic instability or active bleeding (manifested by haematemesis, 
bright red blood per nasogastric tube, or haematochezia). Patients with a resting tachycardia 
≥ 100 beats per minute, a systolic blood pressure < 100 mmHg, orthostatic hypotension (an 
increase in the pulse rate ≥ 20 beats per minute or drop in blood pressure of ≥ 20 mmHg on 
standing), a decrease in haematocrit of ≤ 6%, or transfusion requirement over two units of 
packed red blood cells) should be admitted to an intensive care unit for resuscitation. The 
haemoglobin in high-risk patients should be maintained above 10 g/dL, whereas a 
haemoglobin ≥ 7 g/dL is acceptable in young and otherwise healthy individuals. Patients 
with active bleeding and a bleeding disorder should be transfused with plasma and platelets 
if the INR ≥1.5 and the platelets ≤ 50 000/µL respectively.  
The vital signs (blood pressure, ECG monitoring, and pulse oximetry), clotting profile and 
urinary output should be closely monitored. If indicated, elective endotracheal intubation in 
patients with respiratory failure and decreased consciousness may facilitate endoscopy and 
decrease the risk of aspiration. Patients older than 60 years, with chest pain or a history of 
heart disease should also be evaluated for myocardial infarction with electrocardiograms 
and serial troponin measurements. Nasogastric (NG) tube placement to aspirate and 
characterize gastric contents can be useful to determine if large amounts of red blood, coffee 
- grounds, or non-bloody fluid are present. Patients with definite haematemesis do not need 
an NG tube for diagnostic purposes, but may need one to clear gastric contents before 
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endoscopy and to minimize the risk of aspiration. Approximately 15% of patients without 
bloody or coffee-ground material in nasogastric aspirates are found to have high-risk lesions 
on endoscopy (Aljebreen et al., 2004). 
Clinical and laboratory findings are useful to risk-stratify patients (Table 1). The Blatchford 
score or the clinical Rockall score have been validated as clinical tools in the risk assessment 
(Blatchford et al., 2000; Rockhall et al., 1996). Poor prognostic factors for bleeding peptic 
ulcers include the following: age >60 years, comorbid medical illness, orthostatic 
hypotension, bleeding disorder, bleeding onset in the hospital, multiple blood transfusions 
and red blood in the NG tube. 
 
UGI bleeding
(haematemesis and/or maelena)
Resuscitation and stabilization
Assessment of onset and severity of bleeding
Start intravenous PPIs
Oesophagogastroduodenoscopy
Ulcer
Visible vessel
Forrest  IIa
Active bleeding
Forrest 1a & b 
Clean base
Forrest III
Adherent clot
Forrest IIb
Flat pigmented spot
Forrest IIc
Epinephrine injection +
thermal probe or clip
Thermal probe 
or clip
Epinephrine injection
Dislodge clot with snare or irrigation
Thermal probe 
Early discharge
 
Fig. 1. Approach to upper gastrointestinal (UGI) bleeding. PPIs, proton pump inhibitors. 
4.2 Diagnostic endoscopy 
Its high sensitivity and specificity in identifying and localizing bleeding lesions, makes 
upper endoscopy the diagnostic modality of choice for acute UGIB. Early endoscopy within 
24 hours of presentation, aids risk stratification of patients and reduces the need for 
hospitalization. However, it may also expose additional cases of active bleeding and hence 
increases the use of therapeutic endoscopy. No evidence exists that very early endoscopy 
(within a few hours of presentation) can reduce risk of rebleeding or improve survival (Tsoi 
et al., 2009). 
A large channel therapeutic upper endoscope should be used to allow for rapid removal of 
blood from the stomach and to utilize larger endoscopic hemostasis accessories. Well–
trained assistants who are familiar with endoscopic hemostasis devices are critical to 
successful endoscopic hemostasis. At times it may be worth delaying a procedure in order to 
utilize assistants who are competent at using accessories in emergency situations. Forrest 
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described an endoscopic classification system that is commonly used (Figure 2). At index 
endoscopy the prevalence of ulcers with stigmata of recent haemorrhage, defined as Forrest 
I, IIa and IIb generally accounts for one third and Forrest IIc or III for the remainder (Lau et 
al., 1998) (Figure 2). An adherent clot is defined as a lesion that is red, maroon, or black and 
amorphous in texture which cannot be dislodged by suction or forceful water irrigation) 
(grade IIb). Low-risk lesions include flat, pigmented spots (grade IIc) and clean-base ulcers 
(grade III) (Figure 3). The inter-observer variation in diagnosing these endoscopic stigmata 
is low to moderate. At index endoscopy, high-risk lesions with rebleeding rates from 22% to 
55% are seen in one–third to one–half of all patients. 
 
 
Fig. 2. Endoscopic grading according to Forrest classification 
4.2.1 Preparation for emergency esophagogastroduodenoscopy 
A large-bore orogastric or NG tube with gastric lavage (use tap water at room temperature) 
is useful to improve visualization of the gastric fundus on endoscopy; however, this practice 
has not predictably improved the outcome (Lee et al., 2004). Intravenous erythromycin, as a 
motilin receptor agonist, promotes gastric motility and substantially improves visualization 
of the gastric mucosa at index endoscopy. However, erythromycin does not substantially 
improve the diagnostic yield of endoscopy or the outcome of acute peptic ulcer bleeding. A 
single 250–mg dose of erythromycin 30–60 minutes before endoscopy should be considered 
(Carbonell et al., 2006).  
Empiric intravenous PPI treatment can be initiated prior to endoscopy in patients that 
presents with severe UGIB. Several studies and meta-analyses have shown that this practice 
significantly reduces the proportion of patients with stigmata of recent bleeding at index 
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endoscopy and therefore the need for endoscopic therapy. However, there is no evidence 
that PPI treatment affects clinically important consequences, namely mortality, rebleeding 
or need for surgery (Sreedharan et al., 2010).  
 
 
Fig. 2. Stigmata of bleeding prevalence according to the Forrest classification 
4.2.2 Stratification of the rebleeding risk  
Rebleeding the vital risk factor for mortality increases the rate 5 times compared to patients 
in whom the bleeding has spontaneously stopped (Church et al., 1999; Forrest et al., 1974). 
Predictive models evolved to identify high-risk patients for rebleeding and those for early 
hospital discharge or outpatient care.  
The Rockall scoring system is probably the most widely known risk-stratification tool for 
UGIB. This represents an accurate and validated predictor of rebleeding and death, 
achieving better results in the prediction of mortality (Rockall et al., 1996). The clinical 
Rockall score (i.e. the score before endoscopy) is calculated solely on the basis of clinical 
variables at the time of presentation. For the complete Rockall score the clinical and 
endoscopic stigmata to predict the risks of rebleeding and death are added; the scale ranges 
from 0 to 11 points, with higher scores indicating greater risk.  
The clinical Rockall and Blatchford scores share mutual features that include the patient’s 
hemodynamic status and comorbid illnesses. These might reduce the need for urgent 
endoscopic evaluation in patients deemed at low risk. In addition to clinical and laboratory 
features, endoscopic stigmata can be used to risk-stratify patients that present with acute 
gastric ulcer bleeding (Table 1). 
The endoscopic stigmata of bleeding gastric ulcers provide excellent predictability of the 
likelihood of rebleeding based on the Forrest classification, which ranges from Ia to III. The 
risk for rebleeding varies from 55 – 22% in gastric ulcers if left endoscopically untreated 
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(Laine & Peterson, 1994; Lau et al., 1998). The highest risk is in those with active arterial 
bleeding (grade I), a non-bleeding visible vessel (grade IIa) and an adherent clot (grade IIb). 
Additional data are needed to confirm the possible improvement in risk stratification 
provided by the use of endoscopic Doppler ultrasonography applied directly to the ulcer 
stigmata.  
 
 
Table 1. Risk–stratification tools for UGIB 
4.3 Therapeutic endoscopy 
Gastric ulcers with a high risk of rebleeding should be treated endoscopically at the initial 
endoscopy. Since the late 1980s, endoscopic haemostatic therapy has been widely accepted as 
the first-line therapy for UGIB. Many well–conducted, randomized controlled trials, meta-
analyses, and consensus conferences have confirmed the efficacy of endoscopic therapy in this 
setting (Sacks HS et al. 1990; Cook DJ et al., 1992). These data supported a reduction in 
recurrent bleeding, the need for urgent surgery, and mortality in patients with high–risk 
stigmata (Barkun et al., 2003; Adler et al., 2004). However, most of these studies were 
conducted before the widespread use of PPIs, and predominantly used injection therapy, 
bipolar-probe coagulation therapy, or a combination of injection and coagulation therapy.  
In general, for the highest-risk lesions of active bleeding or non-bleeding visible vessels, 
endoscopic haemostasis alone will decrease the rebleeding rate to approximately 20–25%. 
The adjunctive use of PPIs decreases this rate even further. Endoscopic therapy can be 
broadly categorized into injection therapy, thermal coagulation, and mechanical 
haemostasis. As no single method of endoscopic thermal coagulation therapy is necessarily 
superior. Therefore, a familiar haemostatic technique applicable to the identified ulcer 
stigmata should be used.  
4.3.1 Injection therapy 
Injection therapy is the most commonly used treatment worldwide, mainly because it is 
widely available, easy to perform, safe and inexpensive. A disposable needle is used to inject 
a solution (1:10,000) of diluted adrenaline in normal saline. This mainly has a tamponade-
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effect induced by the volume of solution injected (15–25 ml being a standard dose). 
Although solutions of agents other than adrenaline (such as polidocanol, saline and even 
dextrose) may have a similar effect, none proofed superior in achieving haemostasis. The 
injection of sclerosant (including absolute alcohol) should be avoided as extensive and 
uncontrolled tissue necrosis of the ulcer base can lead to perforation and related 
complications. Adrenaline injection as definite haemostatic therapy is not recommended for 
the risk of rebleeding, but it should be followed either by contact thermal therapy or a 
second injectable agent (e.g. fibrin glue) to avoid further bleeding, the need for surgery and 
mortality in bleeding peptic ulcer (Vergara et al., 2007). This practice reduces the risk of 
perforation and subsequent thermal burn damage that might complicate endoscopic 
therapy.  
4.3.2 Thermal devices  
Thermal devices are the mainstay of endoscopic haemostasis and can be divided into 
contact (heater probe, monopolar and bipolar electrocoagulation) and noncontact types 
(laser treatment, argon plasma coagulation [APC]). Although no single method of 
endoscopic thermal coagulation therapy is superior, electrocoagulation with bipolar contact 
probes is more commonly used. Haemostasis of the underlying vessel is achieved when heat 
is generated during contact of these probes with the bleeding lesion. Thermal contact probes 
can seal arteries up to 2 mm. The risks of thermal probes include perforation and inducing 
more bleeding. While the haemostatic effects of contact probes are well established by 
clinical trials, the use of APC in the treatment of peptic ulcer bleeding has only recently been 
reported. In a randomised, controlled study comparing APC with heater probe coagulation, 
the former proofed equally safe and effective (Chau et al., 2003). No significant differences 
were detected in terms of initial haemostasis at index endoscopy, frequency of recurrent 
bleeding, requirement for emergency surgery, number of units of blood transfused, length 
of hospital stay, and mortality rate.  
4.3.3 Mechanical devices  
Mechanical devices in the form of haemoclips for endoscopic haemostasis in bleeding 
gastric ulcer disease have gained popularity in recent years. In a landmark study by 
Cipolleta and colleagues, they compared haemoclips with heater probe thermocoagulation 
(Cipolletta et al., 2001). The successful application of haemoclips led to a significantly 
decline in recurrent bleeding (1.8% versus 21%). Deployment of haemoclips on fibrotic ulcer 
floors may proof problematic, especially when used tangentially, or with the endoscope 
retroflexed. The difficulty of successful application in these situations may limit the efficacy 
of haemoclips. These technical problems might be overcome with improvements in future 
design.  
4.4 Control of active bleeding or high-risk lesions 
Despite many endoscopists favouring dual endoscopic therapy in patients with severe 
peptic ulcer bleeding, there is currently no definite recommendation in this regard. In 
actively bleeding ulcers, an injection can diminish or even stop bleeding; allowing a clear 
view of the bleeding vessel that in turn facilitates accurate thermal coagulation. 
Theoretically, the cessation of blood flow prevents dissipation of thermal energy, thereby 
minimizing tissue injury.  
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In a systematic review and meta-analysis dual endoscopic therapy proved significantly 
superior to injection therapy alone. However, it had no advantage over thermal or 
mechanical monotherapy to improve the outcome of patients with high-risk peptic ulcer 
bleeding (Marmo et al. 2007). When combining injected substances with thermal coagulation 
in bleeding peptic ulcer disease, there is a significant risk of complications such as 
perforation and gastric wall necrosis. Successful application of haemoclips is comparable to 
thermocoagulation (Sung et al. 2007).  
4.5 Managing an ulcer with an adherent clot  
In the event of an ulcer with an overlying clot, attempting to remove the clot by targeted 
washing is critical. Endoscopic removal of the clot by washing or cold snare has been 
demonstrated to be effective in reducing the recurrence of bleeding (Bini et al., 2003). The 
findings under the clot (e.g. bleeding vessel, visible vessel, flat spot, clean base) help 
determine the therapy needed and improve efficacy by allowing treatment to be applied 
directly to the vessel. A combination of injection with heater probe or bipolar coaptive 
coagulation is often used and has been shown to be more effective in patients with active 
bleeding. Vigorous washing of the clot formed after therapy is useful to determine the 
adequacy of coagulation.  
4.6 Treatment of persistent or recurrent bleeding after initial haemostasis 
Despite the effectiveness of endoscopic haemostasis, rebleeding occurs in 10–25% of cases, 
irrespective of the method of treatment. A second attempt at endoscopic control is 
warranted. Some experts have concerns about the perils of a second endoscopy, which may 
result in delayed surgery, perforation, and increased morbidity and mortality. Combining 
techniques is sensible when re-treating the ulcer site as the first attempt at endoscopic 
therapy might have produced necrosis and weakening of the intestinal wall. By using 
injection as the first step the thickness of the submucosal layer is increased, thus providing 
some margin of safety. 
4.7 Second-look endoscopy 
A planned, second-look endoscopy within 24 hours after initial endoscopic therapy is not 
recommended on the basis of existing evidence (Barkun et al. 2003; Adler et al. 2004). Even 
though it proofed to be efficacious in two meta-analyses that second–look endoscopy with 
heater probe coagulation reduces the risk of recurrent bleeding, it had no overall effect on 
mortality or the need for surgery (Marmo et al. 2003; Tsoi et al. 2009). Also, this approach 
may not be cost-effective when profound acid inhibition is achieved by high-dose 
intravenous PPIs (Spiegel et al. 2003). Second–look endoscopy may be considered in patients 
who are categorized as high risk for rebleeding (shock at presentation, fresh blood in the 
stomach, endoscopic stigmata of active bleeding, large ulcers and high lesser curvature 
gastric ulcers) if adjunctive high–dose intravenous PPI was not commenced. Similarly, if at 
the time of index endoscopy clots obscured the endoscopic view or the efficacy of the 
primary endoscopic haemostasis is doubtful, second-look endoscopy may be indicated 
(Chiu & Sung, 2010).  
4.8 Helicobacter pylori testing 
As one of the main etiological risk factors, all patients with acute bleeding gastric ulcers 
should be tested for Helicobacter pylori infection. Confirmatory testing for Helicobacter pylori 
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in the setting of acute ulcer bleeding may be false negative. Biopsy-based methods, such as 
rapid urease test, histology, and culture, have a low sensitivity, but a high specificity, in 
patients with UGIB. The accuracy of 13C-urea breath test remains very high under these 
circumstances. Stool antigen test is less accurate in UGIB. Although serology seems not to be 
influenced by UGIB, it cannot be recommended as the initial diagnostic test for Helicobacter 
pylori infection in this setting (Gisbert et al., 2006). Treatment of Helicobacter pylori infection is 
more effective than anti–secretory non-eradicating therapy (with or without long-term 
maintenance anti-secretory therapy) in preventing recurrent bleeding from peptic ulcer 
(Gisbert et al., 2004). Therefore, if this infection is not initially detected, it is important to 
repeat the evaluation subsequently to confirm the initial result. The economic impact of this 
strategy, especially in young ulcer patients, must be emphasized. 
5. Pharmacotherapy 
Proton pump inhibitors initiated after endoscopic haemostasis of bleeding peptic ulcer 
significantly reduced rebleeding compared with placebo or H2–receptor antagonists (Sung et 
al., 2009; van Rensburg et al., 2009). The initiation of PPIs before endoscopy significantly 
decreases the proportion of patients with stigmata of a recent bleed (e.g. visible vessel) and a 
need for endoscopic haemostasis, but does not reduce mortality, rebleeding, or surgery risks 
compared with H2–receptor antagonists or placebo (Dorward et al 2006; Lau et al., 2007). 
The effects of PPIs are more pronounced in Asian compared with non–Asian populations. 
There is no role for H2–receptor antagonist, somatostatin, or octreotide in the treatment of 
acute bleeding gastric ulcer.  
The rationale for using acid inhibition in peptic ulcer disease is based on the observation 
that the stability of a blood clot is reduced in an acidic environment. Acid impairs platelet 
aggregation and causes disaggregation. Clot lysis is accelerated predominately by acid-
stimulated pepsin. Furthermore, it may impair the integrity of the mucus-bicarbonate-
barrier. Thus a pH greater than 6 is necessary for platelet aggregation while clot lysis occurs 
when the pH drops below 6.  
5.1 Role of H2–receptor antagonists and somatostatin (octreotide) 
There are no convincing data to support the use of H2–receptor antagonists as these drugs 
do not reliably or consistently increase gastric pH to 6 irrespective of the route of 
administration (Julapalli & Graham, 2005). These drugs had minimal efficay in clinical trials 
and the development of tolerance is a problem.  
Somatostatin and its analogue, octreotide, inhibit both acid and pepsin secretion and reduce 
gastroduodenal mucosal blood flow. However, these drugs are not routinely recommended 
in patients with peptic ulcer bleeding, since contemporary randomized, controlled trials 
have shown little or no benefit attributable to them, either alone or in combination with an 
H2–receptor antagonist. Furthermore, there are no strong data to support the adjunctive use 
of these drugs after endoscopic therapy for ulcer bleeding. (Arabi et al., 2006).  
5.2 Role of proton pump inhibitors 
Proton pump inhibitors can increase the intra-gastric pH > 6.0 for 84 – 99% of the day (Lin et 
al., 1998). Tolerance has not been reported and continuous infusion is superior to 
intermittent bolus administration (Brunner et al., 1996). Pantoprazole given as an initial 80-
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mg bolus injection, followed by 8 mg/h continuous infusion, seems to be the adequate 
treatment in patients with a high risk of rebleeding. Compared to an initial 80 mg–bolus 
injection, followed by 6-mg/h continuous insion, it demonstrated a lower inter-individual 
variability of intra-gastric pH and the pH was ≥ 6 for a greater percentage of time (van 
Rensburg et al. 2003). About five percent of patients with peptic ulcer bleeding responded 
poorly to intravenous omeprazole with rebleeding rates higher in patients with a mean 
intra-gastric pH of less than 6 (Hsieh et al., 2004).  
PPIs in bleeding peptic ulcer have shown to reduce the rebleeding rate and the need for 
surgery, but not mortality whether the patients had an attempt at endoscopic haemostasis or 
not. PPI therapy for ulcer bleeding proofed more efficacious in Asia than elsewhere. This 
may be due to an enhanced pharmacodynamic effect of PPIs in Asian patients (Leontiadis et 
al., 2005). The use of high-dose PPIs (80-mg bolus, followed by 8-mg/h as continuous 
infusion for 72 hours) has been widely studied and used. However, the most effective 
schedule of proton pump PPI administration following endoscopic haemostasis of bleeding 
ulcers remains uncertain. It has been shown in a systemic review and meta-analysis that 
compared with low-dose PPIs, high-dose PPIs do not further reduce the 30–day rates of 
rebleeding, surgical intervention, or mortality after endoscopic treatment in patients with 
bleeding peptic ulcer (Wang et al., 2010).  
5.2.1 Proton pump inhibitors – clinical effectiveness and cost-effectiveness 
Potent acid-suppressing PPIs do not induce tachyphylaxis and have had favorable clinical 
results. Recent meta-analyses showed that the use of proton-pump inhibitors significantly 
decreased the risk of ulcer rebleeding (odds ratio, 0.40; 95% confidence interval [CI], 0.24 to 
0.67), the need for urgent surgery (odds ratio, 0.50; 95% CI, 0.33 to 0.76), and the risk of 
death (odds ratio, 0.53; 95% CI, 0.31 to 0.91), (Bardou et al., 2005; Leontiadis et al., 2006) 
findings that have also been confirmed in a “real-world” setting (Barkun et al., 2004). In 
ulcer bleeding, PPIs reduce rebleeding and the need for surgery and repeated endoscopic 
treatment. PPIs improve mortality among patients at highest risk i.e. patients with active 
bleeding or a non-bleeding visible vessel (Leontiadis et al., 2007) compared with placebo or 
H2–receptor antagonists. PPI treatment initiated prior to endoscopy in UGIB significantly 
reduces the proportion of patients with stigmata of recent bleeding at index endoscopy but 
does not reduce mortality, re-bleeding or the need for surgery. The strategy of giving oral 
PPI before and after endoscopy, with endoscopic haemostatic treatment for those with major 
stigmata of recent haemorrhage, is likely to be the most cost-effective.  
Treatment of Helicobacter pylori infection was found to be more effective than anti-secretory 
therapy in preventing recurrent bleeding from peptic ulcer. Helicobacter pylori eradication 
alone or eradication followed by misoprostol (with switch to PPI, if misoprostol is not 
tolerated) are the two most cost-effective strategies for preventing bleeding ulcers among 
Helicobacter pylori-infected NSAID users, although the data cannot exclude PPIs also being 
cost-effective. Further large randomised controlled trials are needed to address areas such as 
PPI administration prior to endoscopic diagnosis, different doses and administration of 
PPIs, as well as the primary and secondary prevention of UGIB (Leontiadis et al., 2007).  
6. Interventional radiology 
Angiography with transcatheter embolization provides a non-operative method to identify 
and control bleeding when the endoscopic approach fails. Although the technical success 
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rate can be as high as 90–100%, the clinical success rate varies from 50–83% (Cheung et al., 
2009). Embolization might not stop the bleeding permanently. 
7. Surgery 
The role of surgery in acute peptic ulcer bleeding has markedly changed over the past two 
decades. The widespread use of endoscopic treatment has reduced the number of patients 
requiring surgery. Therefore, the need for routine early surgical consultation in all patients 
presenting with acute UGIB is now obviated (Gralnek et al., 2008).  
Emergency surgery should not be delayed, even if the patient is in haemodynamic shock, as 
this may lead to mortality (Schoenberg, 2001). Failure to stop bleeding with endoscopic 
haemostasis and/or interventional radiology is the most important and definite indication. 
The surgical procedures under these circumstances should be limited to achieve 
haemostasis. The widespread use of PPIs obviated further surgical procedures to reduce 
acid secretion. Rebleeding tends to necessitate emergency surgery in approximately 60% of 
cases with an increase in morbidity and mortality (Schoenberg et al.; 2001). The reported 
mortality rates after emergency surgery range from 2 – 36%.  
Whether to consider endoscopic retreatment or surgery for bleeding after initial endoscopic 
control is controversial (Cheung et al., 2009). A second attempt at endoscopic haemostasis is 
often effective (Cheung et al., 2009), with fewer complications avoiding some surgery 
without increasing mortality (Lau et al., 1999). Therefore, most patients with evidence of 
rebleeding can be offered a second attempt at endoscopic haemostasis. This is often 
effective, may result in fewer complications than surgery, and is the current recommended 
management approach.  
Available data suggest that early elective surgery for selected high-risk patients with 
bleeding peptic ulcer might decrease the overall mortality rate. It is a reasonable approach in 
ulcers measuring ≥2 cm or patients with hypotension at rebleeding that independently 
predicts endoscopic retreatment failure (Lau et al., 1999). Early elective surgery in patients 
presenting with arterial bleeding or a visible vessel of ≥2 mm is superior to endoscopic 
retreatment and has a relatively low overall mortality rate of 5% (Imhof et al., 1998 & 2003). 
Additional indications for early elective surgery include age >65 years, previous admission 
for ulcer plication, blood transfusion of more than 6 units in the first 24 hours and 
rebleeding within 48 hours (Bender et al., 1994; Mueller et al., 1994). This approach is 
associated with a low 30–day mortality rate as low as 7%. 
8. Conclusion and recommendations  
Peptic ulcer bleeding, the most common cause for UGIB, is best managed using a 
multidisciplinary approach. The initial clinical evaluation involves an assessment of 
haemodynamic stability and the necessity for fluid replacement. Combined with early 
endoscopic findings (within the first 24 hours), patients can effectively be risk–stratified for 
recurrent ulcer bleeding and managed accordingly. Those patients with active arterial 
bleeding or a visible vessel in the ulcer base should receive combined endoscopic therapy 
(that is, injection and thermal coagulation) as standard of care.  
Despite a lack of concrete evidence of high-dose PPIs being more effective than non–high–
dose PPIs, an 80–mg bolus followed by 8–mg/h as continuous infusion for 72 hours should 
be commenced as this is the only method of administration that reliably achieves the desired 
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high intra-gastric target–pH. Optimal management of bleeding peptic ulcer with an 
adherent clot should probably include an attempt at endoscopic removal, where after the 
same treatment to reduce the risk of recurrent bleeding should be affected. In the event of 
rebleeding after initial successful endoscopic haemostasis repeat–endoscopic therapy should 
be performed rather than surgery with generally a similar outcome with fewer 
complications.  
For refractory bleeding, transcatheter angiography is equally effective as surgery and should 
be considered particularly in patients at high surgical risk. Second–look endoscopy should 
not routinely be performed considering the limited reduction in rebleeding rate and the 
questionable cost-effectiveness as profound acid inhibition is achieved with current medical 
treatment. Critical issues are detecting and eradicating Helicobacter pylori infection and the 
resuming NSAIDs or anti-platelet agents when clinically indicated with co-administration of 
gastro protective agents. 
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